Investigation of Transcript Variant 6 of TPD52L2 as a Prognostic and Predictive Biomarker in Basal-Like MDA-MB-231 and MDA-MB-453 Cell Lines for Breast Cancer

Table 1

Association between the transcript expression of V6 and clinicopathological parameters in breast cancer patients of the BRCA cohort.

Clinicopathological parameters		TPD52L2 expression		value
		High (>median)	Low (<median)
Age
≥60	370	169	201	0.8141
≤60	443	206	237
Her2
Positive	113	59	54	0.1575
Negative	647	288	359
PR
Positive	518	226	292	0.05107
Negative	253	130	123
ER
Positive	597	269	328	0.3822
Negative	177	87	90
Pathologic_M
M0	906	435	471	0.008415
M1	22	17	5
Pathologic_N
N0	513	244	269	0.05549
N1	361	171	190
N2	119	71	48
N3	77	43	34
Pathologic_T
T1	280	114	166	0.000301
T2	629	319	310
T3	138	85	53
T4	40	24	16
Pathologic_stage
Stage I	182	76	106	0.0006917
Stage II	617	297	320
Stage III	249	144	105
Stage IV	20	15	5

Age: at initial pathological diagnosis; pTNM: pathological tumor node metastasis; pT: pathological tumor; pN: pathological node. The median expression value was 4.251. The significance of correlations between V6 expression and clinicopathological parameters was calculated by the test, and Fisher’s exact test was used when the patient number had an expected .